{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,2]],"date-time":"2026-06-02T20:56:52Z","timestamp":1780433812988,"version":"3.54.1"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"2","license":[{"start":{"date-parts":[[2021,5,13]],"date-time":"2021-05-13T00:00:00Z","timestamp":1620864000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Shin Poong Pharmaceutical and Medicines for Malaria Venture"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022,1,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>Pyronaridine-artesunate (PA) is a registered artemisinin-based combination therapy, potentially useful for mass drug administration campaigns. However, further data are needed to evaluate its efficacy, safety and tolerability as full or incomplete treatment in asymptomatic Plasmodium falciparum-infected individuals.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>This phase II, multi-center, open label, randomized clinical trial was conducted in The Gambia and Zambia. Participants with microscopically confirmed asymptomatic P. falciparum infection were randomly assigned (1:1:1) to receive a 3-day, 2-day, or 1-day treatment regimen of PA (180:60 mg), dosed according to bodyweight. The primary efficacy outcome was polymerase chain reaction (PCR)-adjusted adequate parasitological response (APR) at day 28 in the per-protocol population.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>A total of 303 participants were randomized. Day 28 PCR-adjusted APR was 100% for both the 3-day (98\/98) and 2-day regimens (96\/96), and 96.8% (89\/94) for the 1-day regimen. Efficacy was maintained at 100% until day 63 for the 3-day and 2-day regimens but declined to 94.4% (84\/89) with the 1-day regimen. Adverse event frequency was similar between the 3-day (51.5% [52\/101]), 2-day (52.5% [52\/99]), and 1-day (54.4% [56\/103]) regimens; the majority of adverse events were of grade 1 or 2 severity (85% [136\/160]). Asymptomatic, transient increases (&amp;gt;3 times the upper limit of normal) in alanine aminotransferase\/aspartate aminotransferase were observed for 6\/301 (2.0%) participants.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>PA had high efficacy and good tolerability in asymptomatic P. falciparum-infected individuals, with similar efficacy for the full 3-day and incomplete 2-day regimens. Although good adherence to the 3-day regimen should be encouraged, these results support the further investigation of PA for mass drug administration campaigns.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical Trials Registration<\/jats:title>\n                  <jats:p>NCT03814616.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/cid\/ciab425","type":"journal-article","created":{"date-parts":[[2021,5,12]],"date-time":"2021-05-12T19:21:17Z","timestamp":1620847277000},"page":"180-188","source":"Crossref","is-referenced-by-count":7,"title":["Efficacy, Safety and Tolerability of Pyronaridine-artesunate in Asymptomatic Malaria-infected Individuals: a Randomized Controlled Trial"],"prefix":"10.1093","volume":"74","author":[{"given":"Edgard D","family":"Dabira","sequence":"first","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sebastian","family":"Hachizovu","sequence":"additional","affiliation":[{"name":"Tropical Diseases Research Centre, Ndola, Zambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bakary","family":"Conteh","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alieu","family":"Mendy","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haddy","family":"Nyang","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bolarinde","family":"Lawal","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mamadou Ousmane","family":"Ndiath","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce M","family":"Mulenga","sequence":"additional","affiliation":[{"name":"Tropical Diseases Research Centre, Ndola, Zambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sydney","family":"Mwanza","sequence":"additional","affiliation":[{"name":"Tropical Diseases Research Centre, Ndola, Zambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabelle","family":"Borghini-Fuhrer","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture (MMV), Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Arbe-Barnes","sequence":"additional","affiliation":[{"name":"Artemida Pharma Ltd, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Miller","sequence":"additional","affiliation":[{"name":"Artemida Pharma Ltd, Stevenage, United Kingdom"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jangsik","family":"Shin","sequence":"additional","affiliation":[{"name":"Shin Poong Pharmaceutical Co, Ltd, Seoul, Korea"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephan","family":"Duparc","sequence":"additional","affiliation":[{"name":"Medicines for Malaria Venture (MMV), Geneva, Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Umberto","family":"D\u2019Alessandro","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Manyando","sequence":"additional","affiliation":[{"name":"Tropical Diseases Research Centre, Ndola, Zambia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jane","family":"Achan","sequence":"additional","affiliation":[{"name":"Disease Control and Elimination Theme, Medical Research Council Unit, The Gambia at London School of Hygiene & Tropical Medicine, Fajara, The Gambia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2021,5,13]]},"reference":[{"key":"2022012912414391600_CIT0001","author":"World Health Organization","year":"2015"},{"key":"2022012912414391600_CIT0002","author":"World Health Organization","year":"2020"},{"key":"2022012912414391600_CIT0003","doi-asserted-by":"crossref","first-page":"314","DOI":"10.1186\/s12936-015-0829-6","article-title":"On-going malaria transmission in The Gambia despite high coverage of control interventions: a nationwide cross-sectional survey","volume":"14","author":"Mwesigwa","year":"2015","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0004","doi-asserted-by":"crossref","first-page":"e110926","DOI":"10.1371\/journal.pone.0110926","article-title":"School-based countrywide seroprevalence survey reveals spatial heterogeneity in malaria transmission in The Gambia","volume":"9","author":"Okebe","year":"2014","journal-title":"PLoS One"},{"key":"2022012912414391600_CIT0005","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1186\/1475-2875-8-274","article-title":"Comparison of surveillance methods applied to a situation of low malaria prevalence at rural sites in The Gambia and Guinea Bissau","volume":"8","author":"Satoguina","year":"2009","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0006","doi-asserted-by":"crossref","first-page":"e45542","DOI":"10.1371\/journal.pone.0045542","article-title":"The dynamics of natural Plasmodium falciparum infections","volume":"7","author":"Felger","year":"2012","journal-title":"PLoS One"},{"key":"2022012912414391600_CIT0007","doi-asserted-by":"crossref","first-page":"18740","DOI":"10.1038\/s41598-020-75261-9","article-title":"Asymptomatic Plasmodium falciparum malaria prevalence among adolescents and adults in Malawi, 2015\u20132016","volume":"10","author":"Topazian","year":"2020","journal-title":"Sci Rep"},{"key":"2022012912414391600_CIT0008","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1586\/eri.13.45","article-title":"The silent threat: asymptomatic parasitemia and malaria transmission","volume":"11","author":"Lindblade","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"2022012912414391600_CIT0009","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1186\/s12936-019-2906-8","article-title":"Mass drug administration can be a valuable addition to the malaria elimination toolbox","volume":"18","author":"Eisele","year":"2019","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0010","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiaa434","article-title":"Evaluating the impact of programmatic mass drug administration for malaria in Zambia using routine incidence data","author":"Fraser","year":"2020","journal-title":"J Infect Dis"},{"key":"2022012912414391600_CIT0011","doi-asserted-by":"crossref","first-page":"3","DOI":"10.4269\/ajtmh.19-0669","article-title":"Moving from malaria burden reduction toward elimination: an evaluation of mass drug administration in Southern Province, Zambia","volume":"103","author":"Miller","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2022012912414391600_CIT0012","doi-asserted-by":"crossref","first-page":"7","DOI":"10.4269\/ajtmh.19-0659","article-title":"Impact of four rounds of mass drug administration with dihydroartemisinin-piperaquine implemented in Southern Province, Zambia","volume":"103","author":"Eisele","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2022012912414391600_CIT0013","doi-asserted-by":"crossref","first-page":"54","DOI":"10.4269\/ajtmh.19-0657","article-title":"A longitudinal cohort to monitor malaria infection incidence during mass drug administration in Southern Province, Zambia","volume":"103","author":"Bennett","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2022012912414391600_CIT0014","doi-asserted-by":"crossref","first-page":"1831","DOI":"10.1093\/infdis\/jiw416","article-title":"Short-term impact of mass drug administration with dihydroartemisinin plus piperaquine on malaria in Southern Province Zambia: a cluster-randomized controlled trial","volume":"214","author":"Eisele","year":"2016","journal-title":"J Infect Dis"},{"key":"2022012912414391600_CIT0015","author":"World Health Organization","year":"2017"},{"key":"2022012912414391600_CIT0016","doi-asserted-by":"crossref","first-page":"e680","DOI":"10.1016\/S2214-109X(17)30220-6","article-title":"Role of mass drug administration in elimination of Plasmodium falciparum malaria: a consensus modelling study","volume":"5","author":"Brady","year":"2017","journal-title":"Lancet Glob Health"},{"key":"2022012912414391600_CIT0017","doi-asserted-by":"crossref","first-page":"19","DOI":"10.4269\/ajtmh.19-0665","article-title":"Treatment coverage estimation for mass drug administration for malaria with dihydroartemisinin-piperaquine in Southern Province, Zambia","volume":"103","author":"Finn","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2022012912414391600_CIT0018","doi-asserted-by":"crossref","first-page":"37","DOI":"10.4269\/ajtmh.19-0667","article-title":"Adherence to mass drug administration with dihydroartemisinin-piperaquine and Plasmodium falciparum clearance in Southern Province, Zambia","volume":"103","author":"Finn","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2022012912414391600_CIT0019","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1186\/s12879-015-0887-y","article-title":"Mass campaigns with antimalarial drugs: a modelling comparison of artemether-lumefantrine and DHA-piperaquine with and without primaquine as tools for malaria control and elimination","volume":"15","author":"Gerardin","year":"2015","journal-title":"BMC Infect Dis"},{"key":"2022012912414391600_CIT0020","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1186\/1475-2875-12-70","article-title":"Safety and efficacy of pyronaridine-artesunate in uncomplicated acute malaria: an integrated analysis of individual patient data from six randomized clinical trials","volume":"12","author":"Duparc","year":"2013","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0021","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4269\/ajtmh.20-0185","article-title":"Efficacy and safety of pyronaridine-artesunate for the treatment of uncomplicated Plasmodium falciparum and Plasmodium vivax malaria in Myanmar","volume":"103","author":"Han","year":"2020","journal-title":"Am J Trop Med Hyg"},{"key":"2022012912414391600_CIT0022","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1186\/1475-2875-11-364","article-title":"Pyronaridine-artesunate granules versus artemether-lumefantrine crushed tablets in children with Plasmodium falciparum malaria: a randomized controlled trial","volume":"11","author":"Kayentao","year":"2012","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0023","doi-asserted-by":"crossref","first-page":"3884","DOI":"10.1128\/AAC.00039-16","article-title":"Efficacy and safety of pyronaridine-artesunate for treatment of uncomplicated Plasmodium falciparum malaria in Western Cambodia","volume":"60","author":"Leang","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"2022012912414391600_CIT0024","article-title":"Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for the treatment of malaria in Western Cambodia","volume":"63","author":"Leang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022012912414391600_CIT0025","article-title":"Efficacy and safety of pyronaridine-artesunate plus single-dose primaquine for treatment of uncomplicated Plasmodium falciparum malaria in Eastern Cambodia","volume":"63","author":"Leang","year":"2019","journal-title":"Antimicrob Agents Chemother"},{"key":"2022012912414391600_CIT0026","doi-asserted-by":"crossref","first-page":"2187","DOI":"10.1093\/cid\/ciz580","article-title":"Pyronaridine-artesunate efficacy and safety in uncomplicated Plasmodium falciparum malaria in areas of artemisinin-resistant falciparum in Viet Nam (2017\u20132018)","volume":"70","author":"Quang Bui","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022012912414391600_CIT0027","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1086\/591096","article-title":"Fixed-dose pyronaridine-artesunate combination for treatment of uncomplicated falciparum malaria in pediatric patients in Gabon","volume":"198","author":"Ramharter","year":"2008","journal-title":"J Infect Dis"},{"key":"2022012912414391600_CIT0028","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s12936-018-2340-3","article-title":"Pyronaridine-artesunate and artemether-lumefantrine for the treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children: a randomized controlled non-inferiority trial","volume":"17","author":"Roth","year":"2018","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0029","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1056\/NEJMoa1007125","article-title":"Pyronaridine-artesunate versus mefloquine plus artesunate for malaria","volume":"366","author":"Rueangweerayut","year":"2012","journal-title":"N Engl J Med"},{"key":"2022012912414391600_CIT0030","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1016\/S0140-6736(10)60322-4","article-title":"Efficacy and safety of a fixed-dose oral combination of pyronaridine-artesunate compared with artemether-lumefantrine in children and adults with uncomplicated Plasmodium falciparum malaria: a randomised non-inferiority trial","volume":"375","author":"Tshefu","year":"2010","journal-title":"Lancet"},{"key":"2022012912414391600_CIT0031","first-page":"CD006404","article-title":"Pyronaridine-artesunate for treating uncomplicated Plasmodium falciparum malaria","volume":"1","author":"Pryce","year":"2019","journal-title":"Cochrane Database Syst Rev"},{"key":"2022012912414391600_CIT0032","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1016\/S0140-6736(18)30291-5","article-title":"Pyronaridine-artesunate or dihydroartemisinin-piperaquine versus current first-line therapies for repeated treatment of uncomplicated malaria: a randomised, multicentre, open-label, longitudinal, controlled, phase 3b\/4 trial","volume":"391","author":"West African Network for Clinical Trials of Antimalarial D","year":"2018","journal-title":"Lancet"},{"key":"2022012912414391600_CIT0033","author":"World Health Organization & UNICEF\/UNDP\/World Bank\/WHO Special Programme for Research and Training in Tropical Diseases","year":"2015"},{"key":"2022012912414391600_CIT0034","author":"World Health Organization","year":"2008"},{"key":"2022012912414391600_CIT0035","doi-asserted-by":"crossref","first-page":"00394","DOI":"10.1128\/AAC.00394-18","article-title":"Superior pyronaridine single-dose pharmacodynamics compared to artesunate, chloroquine, and amodiaquine in a murine malaria luciferase model","volume":"62","author":"Okoth","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2022012912414391600_CIT0036","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/1475-2875-8-31","article-title":"The last man standing is the most resistant: eliminating artemisinin-resistant malaria in Cambodia","volume":"8","author":"Maude","year":"2009","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0037","doi-asserted-by":"crossref","first-page":"2196","DOI":"10.1093\/cid\/ciz583","article-title":"Pyronaridine-artesunate shows promise as an effecive and well-tolerated treatment for artemisinin-resistant Plasmodium falciparum malaria","volume":"70","author":"Okombo","year":"2020","journal-title":"Clin Infect Dis"},{"key":"2022012912414391600_CIT0038","first-page":"CD007483","article-title":"Artemisinin-based combination therapy for treating uncomplicated malaria","author":"Sinclair","year":"2009","journal-title":"Cochrane Database Syst Rev"},{"key":"2022012912414391600_CIT0039","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1186\/1475-2875-10-263","article-title":"Review of the clinical pharmacokinetics of artesunate and its active metabolite dihydroartemisinin following intravenous, intramuscular, oral or rectal administration","volume":"10","author":"Morris","year":"2011","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0040","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1186\/s12916-016-0621-7","article-title":"Gametocyte carriage in uncomplicated Plasmodium falciparum malaria following treatment with artemisinin combination therapy: a systematic review and meta-analysis of individual patient data","volume":"14","author":"WWARN Gametocyte Study Group","year":"2016","journal-title":"BMC Med"},{"key":"2022012912414391600_CIT0041","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1186\/1475-2875-7-125","article-title":"Reduction of transmission from malaria patients by artemisinin combination therapies: a pooled analysis of six randomized trials","volume":"7","author":"Okell","year":"2008","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0042","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/S1383-5769(99)00028-8","article-title":"Gametocytocidal activity of pyronaridine and DNA topoisomerase II inhibitors against multidrug-resistant Plasmodium falciparum in vitro","volume":"48","author":"Chavalitshewinkoon-Petmitr","year":"2000","journal-title":"Parasitol Int"},{"key":"2022012912414391600_CIT0043","doi-asserted-by":"crossref","first-page":"E1214","DOI":"10.1073\/pnas.1112037108","article-title":"Quantitative assessment of Plasmodium falciparum sexual development reveals potent transmission-blocking activity by methylene blue","volume":"108","author":"Adjalley","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2022012912414391600_CIT0044","doi-asserted-by":"crossref","first-page":"3268","DOI":"10.1128\/AAC.00325-13","article-title":"Male and female Plasmodium falciparum mature gametocytes show different responses to antimalarial drugs","volume":"57","author":"Delves","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2022012912414391600_CIT0045","doi-asserted-by":"crossref","first-page":"e35019","DOI":"10.1371\/journal.pone.0035019","article-title":"Activity of clinically relevant antimalarial drugs on Plasmodium falciparum mature gametocytes in an ATP bioluminescence \u201ctransmission blocking\u201d assay","volume":"7","author":"Leli\u00e8vre","year":"2012","journal-title":"PLoS One"},{"key":"2022012912414391600_CIT0046","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1186\/s12936-018-2373-7","article-title":"Plasmodium falciparum gametocyte dynamics after pyronaridine-artesunate or artemether-lumefantrine treatment","volume":"17","author":"Roth","year":"2018","journal-title":"Malar J"},{"key":"2022012912414391600_CIT0047","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1186\/s12916-016-0581-y","article-title":"Single low dose primaquine to reduce gametocyte carriage and Plasmodium falciparum transmission after artemether-lumefantrine in children with asymptomatic infection: a randomised, double-blind, placebo-controlled trial","volume":"14","author":"Gon\u00e7alves","year":"2016","journal-title":"BMC Med"},{"key":"2022012912414391600_CIT0048","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ebiom.2016.10.032","article-title":"The gametocytocidal efficacy of different single doses of primaquine with dihydroartemisinin-piperaquine in asymptomatic parasite carriers in The Gambia: a randomized controlled trial","volume":"13","author":"Okebe","year":"2016","journal-title":"EBioMedicine"},{"key":"2022012912414391600_CIT0049","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/S1473-3099(15)00318-7","article-title":"Safety and efficacy of re-treatments with pyronaridine-artesunate in African patients with malaria: a substudy of the WANECAM randomised trial","volume":"16","author":"Sagara","year":"2016","journal-title":"Lancet Infect Dis"},{"key":"2022012912414391600_CIT0050","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/j.jinf.2015.08.005","article-title":"Is asymptomatic malaria really asymptomatic? Hematological, vascular and inflammatory effects of asymptomatic malaria parasitemia","volume":"71","author":"de Mast","year":"2015","journal-title":"J Infect"},{"key":"2022012912414391600_CIT0051","doi-asserted-by":"crossref","first-page":"970","DOI":"10.4269\/ajtmh.18-0233","article-title":"Molecular detection of residual parasitemia after pyronaridine-artesunate or artemether-lumefantrine treatment of uncomplicated Plasmodium falciparum malaria in Kenyan children","volume":"99","author":"Roth","year":"2018","journal-title":"Am J Trop Med Hyg"}],"container-title":["Clinical Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/cid\/advance-article-pdf\/doi\/10.1093\/cid\/ciab425\/38958785\/ciab425.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/2\/180\/42332314\/ciab425.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/cid\/article-pdf\/74\/2\/180\/42332314\/ciab425.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,29]],"date-time":"2022-01-29T12:42:18Z","timestamp":1643460138000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/cid\/article\/74\/2\/180\/6275208"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,5,13]]},"references-count":51,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,5,13]]},"published-print":{"date-parts":[[2022,1,29]]}},"URL":"https:\/\/doi.org\/10.1093\/cid\/ciab425","relation":{},"ISSN":["1058-4838","1537-6591"],"issn-type":[{"value":"1058-4838","type":"print"},{"value":"1537-6591","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2022,1,15]]},"published":{"date-parts":[[2021,5,13]]}}}